Browsing Tag
Travere Therapeutics Inc.
1 post
Everest Medicines closes $1.14bn Travere deal for rare kidney disease drug
Everest Medicines closes its $1.14 billion Travere deal for civorebrutinib. Read how the BTK licence reshapes 1952.HK, TVTX and rare kidney strategy.